carboplatin + vindesine

Carboplatin + vindesine is a combination chemotherapy regimen consisting of two cytotoxic agents, carboplatin and vindesine. Carboplatin is an organoplatinum alkylating agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. Vindesine is a vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis and cell division. This combination has been studied primarily for the treatment of non-small cell lung cancer (NSCLC), where it was found to be less toxic and more convenient than cisplatin-based regimens but with similar survival outcomes. The most common side effect observed was mild to moderate leukopenia[1].